Journal of Psychedelic Studies
October 24, 2022
Elizabeth Wolfson
12 citations
Abstract A renaissance is underway as research studies are substantiating psychotherapeutic and physiological benefits of psychedelic medicines, along with advancements towards legalization, expansion of professional training programs and a renewed cultural recognition of the healing qualities of the medicines. Pending legislation, a cadre of trained psychotherapists are poised to apply their...
October 18, 2022
Paul Liknaitzky
Psychedelic therapies have the potential to treat mental illness but there’s still a long way to go. After decades in the wilderness, psychedelic therapies are making a comeback into clinical research and are poised to re-enter medical care. When used alongside psychotherapy, drugs like psilocybin (found in ‘magic mushrooms’) and MDMA (found in ‘ecstasy’) have […]
Alcoholism & Drug Abuse Weekly
October 14, 2022
Alison Knopf
The beneficial effects of psilocybin‐assisted psychotherapy on alcohol use disorder (AUD) are significant, based on a study published in JAMA Psychiatry last month. In general, psychedelic medications have been a focus of research, but less is known about psilocybin, and it has been 40 years since the studies with lysergic acid diethylamide (LSD) provided double the remissions as comparison...
October 10, 2022
Malcolm Hopwood
Therapy is turning to drugs previously known for being illicit party substances. But there’s no reason to abandon proper trials. A range of new therapies for mental illness were previously considered unthinkable — party drugs including ketamine, medicinal cannabis and psychedelics like MDMA, psilocybin and DMT. With mental health disorders a growing cause of disability […]
October 5, 2022
Terence H. W. Ching, Stephen A. Kichuk, Giuliana DePalmer et al.
5 citations
preprint
The Yale Program for Psychedelic Science (YPPS) is testing the safety and efficacy of psilocybin, administered in conjunction with non-directive psychological support, as a treatment for certain neurological and psychiatric conditions. The study, HIC: 200020355 (Neural correlates of the effects of psilocybin in obsessive-compulsive disorder: A double-blind, placebo-controlled study), will...
Genetic Engineering & Biotechnology News
October 1, 2022
K. Liszewski
A new model of psilocybin therapy is being developed by Compass Pathways, a mental health company. This model involves the administration of a synthetic psilocybin in conjunction with psychological support in order to treat conditions such as treatment-resistant depression. Most recently, Compass announced the launch of a Phase II trial to investigate the efficacy of its synthetic psilocybin...
Brain, Behavior, & Immunity - Health
October 1, 2022
S. Parekh, Lydia Adams, Gillian A. Barkell et al.
7 citations
Post-traumatic stress disorder (PTSD) is a devastating disorder that involves maladaptive changes in immune status. Using the stress-enhanced fear learning (SEFL) paradigm, an animal model of PTSD, our laboratory has demonstrated increased pro-inflammatory cytokine immunoreactivity in the hippocampus following severe stress. Recent clinical trials have demonstrated...
Drug and Alcohol Dependence
October 1, 2022
Otto Simonsson, Simon B. Goldberg, Richard Chambers et al.
16 citations
Previous studies have reported links between classic psychedelic use and seizures, but little remains known about prevalence and potential risk factors of classic psychedelic-related seizures. Using a sample representative of the US adult population with regard to sex, age, and ethnicity (N = 2822), this study examined the prevalence and potential risk factors of classic psychedelic-related...
Journal of Pain
October 1, 2022
Robert H. Dworkin, Brian T Anderson, Nick Andrews et al.
22 citations
Psychedelic substances have played important roles in diverse cultures, and ingesting various plant preparations to evoke altered states of consciousness has been described throughout recorded history. Accounts of the subjective effects of psychedelics typically focus on spiritual and mystical-type experiences, including feelings of unity, sacredness, and transcendence. Over the past 2 decades,...
Pharmacological Reviews
October 1, 2022
Anna U. Odland, Jesper L. Kristensen, Jesper T. Andreasen
23 citations
Psychedelic-assisted psychotherapy holds great promise in the treatment of mental health disorders. Research into 5-hydroxytryptamine 2A receptor (5-HT2AR) agonist psychedelic compounds has increased dramatically over the past two decades. In humans, these compounds produce drastic effects on consciousness, and their therapeutic potential relates to changes in the processing of emotional,...